Compare SPTX & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPTX | CHY |
|---|---|---|
| Founded | N/A | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2026 | 2003 |
| Metric | SPTX | CHY |
|---|---|---|
| Price | $24.31 | $13.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 104.0K | ★ 172.7K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.59 | $10.41 |
| 52 Week High | $26.32 | $13.91 |
| Indicator | SPTX | CHY |
|---|---|---|
| Relative Strength Index (RSI) | 65.81 | 47.52 |
| Support Level | $18.72 | $12.06 |
| Resistance Level | N/A | $13.11 |
| Average True Range (ATR) | 1.44 | 0.17 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 70.22 | 33.57 |
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.